PRL and B-cell chronic lymphocytic leukemia: In a phase 1–2 study in 61 patients with relapsed CLL and a median of three prior therapies, acalabrutinib produced an ORR of 95% (85% PR and 10% PRL); all patients with del(17p) responded70.